An interventional study of Sucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C and Routine perioperative management in Anemia, Iron Deficiencies and Cardiac Surgery, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Anemia with a site in China — 32 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.
Among the 116 studies in Anemia with a site in China, this one is the 13th largest by planned enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2026, is one of 20 with no phase, reaches primary completion later than 41 of the 41 other live ones, and was the 101st registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →32 of the 116 studies in Anemia with a site in China are open now. Recruiting first, the newest first:
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
Kind Pharmaceuticals LLC · Sites in China
Ages 18–75
Zhujiang Hospital · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Healthy volunteers
The First Affiliated Hospital of Dalian Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 30 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 120 across the 98 interventional studies, 800 across the 18 observational. Of the 46 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 116 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.
Second Affiliated Hospital, School of Medicine, Zhejiang University has 5 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
14 of the studies in Anemia with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07494409Phase 3Kind Pharmaceuticals LLCA Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | 2027-02-20 |
| NCT07487727Phase 3Kind Pharmaceuticals LLCA Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | 2027-03-01 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06946394The First Affiliated Hospital of Dalian Medical UniversityUse of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI | 2026-12 |
| NCT07136792Guangdong Provincial People's HospitalA Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 116 studies in Anemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a sub-study of the Preoperative Combined Iron Therapy trail in which some participants will be additionally randomized to combined iron supplementation or standarded treatment control to evaluate the impact on long-term outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery. All perioperative transfusion decisions will follow standardized restrictive transfusion thresholds
Drug: Sucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C
Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices
Procedure: Routine perioperative management
Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.
Also known as: Routine perioperative management
Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.
Quality of Life (EQ-5D)
Assessment of health-related quality of life using the EuroQol 5-Dimension (EQ-5D) questionnaire
Time frame: 1 year postoperatively (±30 days)
Sleep Quality (Pittsburgh Sleep Quality Index, PSQI)
Evaluation of sleep quality using the Pittsburgh Sleep Quality Index (PSQI)
Time frame: 1 year postoperatively (±30 days)
Fatigue (FACIT-Fatigue Scale)
Measurement of fatigue level using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.
Time frame: 1 year postoperatively (±30 days)
All-cause Complications
Occurrence of any postoperative complications from any cause during the 1-year follow-up period
Time frame: Up to 1 year postoperatively
Hospital Readmission
Any hospital readmission for any cause within 1 year after surgery.
Time frame: Up to 1 year postoperatively
Repeat Cardiac Surgery
Any subsequent cardiac surgery (reoperation) within 1 year after the index surgery.
Time frame: Up to 1 year postoperatively
All-cause Mortality
Death from any cause within 1 year after surgery.
Time frame: Up to 1 year postoperatively
Plan to share: Undecided
Started Mar 2026 (actual). Primary completion is estimated for Jun 2029, 39 months after the start.
Of 165 non-industry interventional studies with no phase under Anemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 39 months is above that.
Counting every sponsor, half of 179 studies reached it within 17 months; a quarter within 7 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University →